Apoliprotein c-iii (apo c-iii) inhibitors effect of antisense oligonucleotides in the management

HIGHLIGHTS

• who: I Gede Aswin Parisya et al. from the Faculty of Medicine, Universitas Udayana have published the paper: Apoliprotein C-III (Apo C-III) inhibitors effect of antisense oligonucleotides in the management, in the Journal: (JOURNAL)
• what: The final evaluation of the study showed that 75% of the group of patients who were given ISIS 304801 200 mg and 91% of the group that was given a dose of 300 mg had blood cholesterol levels below 200 mg per dL .
• how: These data showed that when given 50mg/kg per week of ASO . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.